7 Days in 7 News: September 5-11, 2025 – Medscape
- The week of September 5th to 11th, 2025, saw significant movement in several areas of medical research and practice.
- A major focus this week was on the continued progress of targeted cancer therapies.
- Key Takeaway: The integration of targeted therapies with immunotherapy is rapidly becoming a cornerstone of NSCLC treatment, offering hope for more durable responses and improved quality of life.
Key Medical Developments: September 5-11, 2025
Table of Contents
- Key Medical Developments: September 5-11, 2025
- Cancer Research: Breakthroughs in Targeted Therapies
- Cardiovascular Health: Updated Cholesterol Guidelines
- Infectious Diseases: Rising Concerns Over antibiotic Resistance
- Mental Health: Teletherapy Access Expands
- Neurology: Advances in Alzheimer’s Disease Diagnostics
- The Phrase of the week: “Precision Medicine”
The week of September 5th to 11th, 2025, saw significant movement in several areas of medical research and practice. From advancements in cancer treatment to evolving guidelines on cardiovascular health, here’s a breakdown of the most crucial developments.
Cancer Research: Breakthroughs in Targeted Therapies
A major focus this week was on the continued progress of targeted cancer therapies. Researchers presented compelling data at the European Society for Medical Oncology (ESMO) Congress on September 9th, 2025, demonstrating improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) treated with a novel combination of immunotherapy and a targeted kinase inhibitor. The study, published concurrently in The lancet Oncology, showed a statistically significant increase in progression-free survival compared to standard chemotherapy regimens. The Lancet Oncology
Cardiovascular Health: Updated Cholesterol Guidelines
On September 7th, 2025, the American Heart Association (AHA) released updated guidelines for the management of cholesterol. These revisions, the first in seven years, place greater emphasis on individualized risk assessment and the use of newer lipid-lowering agents, including PCSK9 inhibitors. The AHA now recommends considering PCSK9 inhibitors for a broader range of patients at high cardiovascular risk, even if they are already on maximum doses of statins. American heart Association
Data Visualization Placeholder
Infectious Diseases: Rising Concerns Over antibiotic Resistance
Public health officials expressed growing concern this week over the increasing prevalence of antibiotic-resistant bacteria. The Centers for Disease Control and Prevention (CDC) reported a significant rise in cases of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in several hospitals across the United States. Centers for Disease Control and Prevention This trend underscores the urgent need for improved infection control practices and the development of new antibiotics.
Antibiotic resistance is a critical threat to public health. We must act now to preserve the effectiveness of these life-saving medications.
Mental Health: Teletherapy Access Expands
A significant development in mental healthcare access occurred on September 10th, 2025, when the Department of Health and Human Services (HHS) announced a permanent expansion of telehealth coverage for mental health services.This policy, initially implemented during the COVID-19 pandemic, will now allow patients to continue receiving therapy remotely, regardless of thier location. U.S. Department of Health & Human Services
Neurology: Advances in Alzheimer’s Disease Diagnostics
Researchers at the National Institutes of Health (NIH) unveiled a new blood test on September 6th, 2025, capable of detecting early biomarkers of Alzheimer’s disease with greater accuracy than previous methods. The test measures levels of phosphorylated tau protein in the blood, a key indicator of amyloid plaque buildup in the brain. National Institutes of Health This breakthrough could lead to earlier diagnosis and intervention, perhaps slowing the progression of the disease.